Biotech Layoff Wave Hits Karyopharm, Century, and Pacira in 2025
Karyopharm Therapeutics conducted its second round of layoffs in 2025, eliminating approximately 20% of its workforce after strategic options failed to materialize.13
Century Therapeutics cut 51% of its staff and terminated two executives to focus on its highest-potential programs, representing one of the most significant workforce reductions in the current wave.135
Pacira shut down its Exparel production facility in San Diego, resulting in 71 jobs lost, about 8% of its workforce; the company aims to cut about $13 million in annual operating expenses due to these layoffs.15
The first half of 2025 has seen a 32% year-over-year increase in biopharma layoffs, with May reaching a four-year high for reported reductions in force.4
These layoffs reflect broader challenges in the biotech sector, including increased competition, clinical trial disruptions, and ongoing efforts to reduce costs amid shifting strategic priorities.1234
Sources:
1. https://www.thelayoff.com/t/1jzxrvzw9
2. https://www.biopharmadive.com/news/karyopharm-biotech-layoffs-restructuring-xpovio/689685/
3. https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025
4. https://www.fiercebiotech.com/biotech/biopharma-layoffs-first-half-year-jump-32-yoy